The 2017 Market for Research Antibodies: Keys to Success for Commercial Suppliers
|出版日期||內容資訊||英文 91 Pages
|研究用抗體的市場 (2017年):對商業供應商來說的成功的關鍵 The 2017 Market for Research Antibodies: Keys to Success for Commercial Suppliers|
|出版日期: 2017年07月17日||內容資訊: 英文 91 Pages||
The 2017 Market for Research Antibodies: Keys to Success for Commercial Suppliers is BioInformatics LLC's newest report, a comprehensive analysis of this lucrative market. Designed specifically for suppliers of commercial, pre-made catalog antibodies, this primary research report identifies scientists' expectations and preferences with regards to usage, brands, purchasing, product quality and budgets. For companies competing in the antibodies market and for those about to enter, key findings highlight market share, competitive positioning, customer satisfaction and how well current products meet researchers' needs. Additionally, the report identifies “best in class” vendors by application and by the most widely-used techniques, all of which identify gaps that present opportunities for antibodies suppliers.
The 2017 Market for Research Antibodies: Keys to Success for Commercial Suppliers is a valuable resource for understanding the various criteria laboratories use to choose their antibodies suppliers and the critical touchpoints in the purchasing process where suppliers can influence this decision. More specifically, how antibodies are ordered is documented, with an emphasis on typical size of purchases, average spend, projected spend, preferred ordering channels and likelihood to repurchase.
For suppliers that are seeking ways to differentiate their products in this competitive market, The 2017 Market for Research Antibodies: Keys to Success for Commercial Suppliers highlights what more than 1,000 scientists from laboratories around the world indicate would help them achieve their research objectives. At strategic and tactical levels, suppliers can use this report with confidence to make decisions about developing and marketing commercial, pre-made catalog antibodies.